Halozyme Therapeutics President and CEO Helen Torley Sells $6M of Stock
Helen Torley, President and CEO, sold 60,000 shares of Halozyme Therapeutics, Inc. at $96.85 to $101.72 a share (average $100.01) in 10 transactions, worth $6M in total between Nov 12, 2026 and Nov 16, 2026. Shares held after the trade: 767,780 (-0.0%).
Halozyme Therapeutics President and CEO Helen Torley Sells $6.61M of Stock
Helen Torley, President and CEO, sold 60,000 shares of Halozyme Therapeutics, Inc. at $107.90 to $113.69 a share (average $110.18) in 12 transactions, worth $6.61M in total between Oct 6, 2026 and Oct 8, 2026. Shares held after the trade: 767,780 (-0.0%).
Halozyme Therapeutics Insider Matthew L. Posard Sells $568K of Stock
Matthew L. Posard sold 5,230 shares of Halozyme Therapeutics, Inc. at $107.17 to $110.04 a share (average $108.54) in 4 transactions, worth $568K in total on Oct 1, 2026. Shares held after the trade: 53,609 (-0.2%).
Halozyme Therapeutics President and CEO Helen Torley Sells $6.44M of Stock
Helen Torley, President and CEO, sold 60,000 shares of Halozyme Therapeutics, Inc. at $107.01 to $108.67 a share (average $107.28) in 7 transactions, worth $6.44M in total between Sep 9, 2026 and Sep 11, 2026. Shares held after the trade: 767,780 (-0.6%).